| Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia JA Fraietta, SF Lacey, EJ Orlando, I Pruteanu-Malinici, M Gohil, S Lundh, ... Nature medicine 24 (5), 563-571, 2018 | 1388 | 2018 |
| CRISPR-engineered T cells in patients with refractory cancer EA Stadtmauer, JA Fraietta, MM Davis, AD Cohen, KL Weber, E Lancaster, ... Science 367 (6481), eaba7365, 2020 | 1169 | 2020 |
| Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells OU Kawalekar, RS O’Connor, JA Fraietta, L Guo, SE McGettigan, ... Immunity 44 (2), 380-390, 2016 | 1103 | 2016 |
| Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells JA Fraietta, CL Nobles, MA Sammons, S Lundh, SA Carty, TJ Reich, ... Nature 558 (7709), 307-312, 2018 | 709 | 2018 |
| Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell M Ruella, J Xu, DM Barrett, JA Fraietta, TJ Reich, DE Ambrose, ... Nature medicine 24 (10), 1499-1503, 2018 | 561 | 2018 |
| Decade-long leukaemia remissions with persistence of CD4+ CAR T cells JJ Melenhorst, GM Chen, M Wang, DL Porter, C Chen, MKA Collins, ... Nature 602 (7897), 503-509, 2022 | 529 | 2022 |
| Dominant-negative TGF-β receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication CC Kloss, J Lee, A Zhang, F Chen, JJ Melenhorst, SF Lacey, MV Maus, ... Molecular therapy 26 (7), 1855-1866, 2018 | 508 | 2018 |
| An introduction to chimeric antigen receptor (CAR) T‐cell immunotherapy for human cancer S Feins, W Kong, EF Williams, MC Milone, JA Fraietta American journal of hematology 94 (S1), S3-S9, 2019 | 498 | 2019 |
| Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma LA Johnson, J Scholler, T Ohkuri, A Kosaka, PR Patel, SE McGettigan, ... Science translational medicine 7 (275), 275ra22-275ra22, 2015 | 496 | 2015 |
| Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia JA Fraietta, KA Beckwith, PR Patel, M Ruella, Z Zheng, DM Barrett, ... Blood, The Journal of the American Society of Hematology 127 (9), 1117-1127, 2016 | 495 | 2016 |
| Ibrutinib treatment improves T cell number and function in CLL patients M Long, K Beckwith, P Do, BL Mundy, A Gordon, AM Lehman, ... The Journal of clinical investigation 127 (8), 3052-3064, 2017 | 355 | 2017 |
| The microRNA miR-155 controls CD8+ T cell responses by regulating interferon signaling DT Gracias, E Stelekati, JL Hope, AC Boesteanu, TA Doering, J Norton, ... Nature immunology 14 (6), 593-602, 2013 | 340 | 2013 |
| Adoptive immunotherapy for cancer or viruses MV Maus, JA Fraietta, BL Levine, M Kalos, Y Zhao, CH June Annual review of immunology 32, 189-225, 2014 | 329 | 2014 |
| Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells S Ghassemi, S Nunez-Cruz, RS O'Connor, JA Fraietta, PR Patel, ... Cancer immunology research 6 (9), 1100-1109, 2018 | 243 | 2018 |
| IFNγ and CCL2 cooperate to redirect tumor-infiltrating monocytes to degrade fibrosis and enhance chemotherapy efficacy in pancreatic carcinoma KB Long, WL Gladney, GM Tooker, K Graham, JA Fraietta, GL Beatty Cancer discovery 6 (4), 400-413, 2016 | 242 | 2016 |
| PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial V Narayan, JS Barber-Rotenberg, IY Jung, SF Lacey, AJ Rech, MM Davis, ... Nature medicine 28 (4), 724-734, 2022 | 231 | 2022 |
| The Addition of the BTK inhibitor Ibrutinib to anti-CD19 chimeric antigen receptor T cells (CART19) improves responses against mantle cell lymphoma M Ruella, SS Kenderian, O Shestova, JA Fraietta, S Qayyum, Q Zhang, ... Clinical Cancer Research 22 (11), 2684-2696, 2016 | 195 | 2016 |
| T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma AL Garfall, EK Dancy, AD Cohen, WT Hwang, JA Fraietta, MM Davis, ... Blood advances 3 (19), 2812-2815, 2019 | 158 | 2019 |
| Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy JAC van Bruggen, AWJ Martens, JA Fraietta, T Hofland, SH Tonino, ... Blood, The Journal of the American Society of Hematology 134 (1), 44-58, 2019 | 154 | 2019 |
| Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing A Dimitri, F Herbst, JA Fraietta Molecular cancer 21 (1), 78, 2022 | 143 | 2022 |
Carl JuneUniversity of Pennsylvania在 upenn.edu 的电子邮件经过验证
